SINGAPORE, April 1, 2026 /PRNewswire/ — PieBox, the one-stop AI development platform highly anticipated by the technology and developer communities, announced its official launch today. As a revolutionary AI full-lifecycle development workspace, PieBox is dedicated to breaking the limitations of current AI programming tools that only generate “one-time demo” applications. By leveraging an industry-leading multi-model intelligent dispatch system, exceptional complex task orchestration capabilities, and exclusive support for local deployment, PieBox, a brand owned by SPARKHUB PTE. LTD., truly helps creators and enterprises achieve a complete commercial closed loop from idea, development, and deployment to ultimate monetization.

I. Product Positioning: A Complete Workspace from “Idea to Revenue”

In today’s landscape where AI tools are blossoming everywhere, the evolution of traditional programming tools mostly remains at the stage of “intelligent code editors.” The positioning of PieBox is instead a highly efficient “rapid application factory.”

Most AI tools can only help users create presentation-level demos that are opened once and never used again. However, a real commercial product requires stable deployment, a secure login system, and reliable payment integration. These elements are the massive watershed between “lookable” and “usable.” The purpose of PieBox’s existence is to help users cross this exact line. PieBox is not a simple replacement for local development. It is a unified platform designed for those who are serious about building products. It achieves full-lifecycle coverage from programming, publishing, and promotion to data analysis, allowing users to easily realize the concept of “All by Chatting, All in One.” It empowers users to “build a business, not just a toy.“

II. Solving Core Pain Points: Bidding Farewell to Single-Model Bottlenecks and the “Half-Finished” Dilemma

The current AI development field generally faces pain points such as unstable code quality, the inability to land complex projects, and data privacy leaks. PieBox provides disruptive solutions specifically targeted at these issues:

1. Breaking Single-Model Limitations with Pioneering Multi-Model Collaborative Dispatch

Currently, most AI programming tools on the market are often limited by the capability ceiling of a single model. PieBox innovatively breaks this barrier by comprehensively aggregating flagship models from top global AI vendors such as OpenAI, Google, Anthropic, and xAI. Relying on the platform’s built-in intelligent dispatch system, PieBox can automatically deploy the best resources for different development stages. Front-end UI construction is handed over to Google’s strongest visual model. Complex logical deduction is solved by OpenAI’s top reasoning model. Core code and task orchestration are led by Anthropic’s strongest programming model, while real-time information retrieval utilizes xAI’s high-speed model. Various top-tier AI agents collaborate seamlessly and perform their respective duties, completely eliminating the capability blind spots of single models when dealing with complex commercial projects.

2. Exceptional Task Orchestration and Extremely High One-Shot Success Rate

Traditional AI code generation often traps developers in a quagmire of repeated debugging and modification. PieBox completely overturns this status quo with its industry-leading complex task breakdown and automated orchestration capabilities. Facing massive commercial-grade project requirements, PieBox takes only 3 to 5 minutes to complete the rapid orchestration from logical breakdown to code generation, directly delivering high-quality code that meets production standards. The extremely high “One-Shot Success” rate allows developers to completely bid farewell to the endless cycle of being bogged down in “prompt fine-tuning,” returning their core energy to product innovation and commercial monetization.

3. Resolving Enterprise Privacy Anxiety with Exclusive Support for Full Local Deployment

PieBox has completely broken down the barriers of development environments, achieving seamless collaboration and state synchronization across three platforms: CLI, Desktop, and Cloud. At the same time, PieBox provides an extremely flexible underlying architecture. You can either conveniently access PieBox Cloud to enjoy cloud agility, or choose to deploy the entire system on your enterprise’s own infrastructure. Paired with self-built or privatized large model services, this achieves complete physical isolation and autonomous control of core code and commercial data.

III. Core Users: Empowering Action-Oriented Individuals Pursuing Quality and Commercialization

The core target audience of PieBox consists of teams and individuals who not only need code but also need to push their products to the market:

• Entrepreneurs and small teams needing to quickly validate application ideas: From inspiration to product prototype and then to online testing, PieBox helps users shorten the trial-and-error cycle.
• R&D teams with requirements for code quality and delivery efficiency: It is particularly suitable for teams hoping to improve the delivery efficiency of complex projects and reduce inefficient repetitive work.
• Enterprise clients with clear requirements for local deployment and privacy security: This includes industries like finance, healthcare, and other scenarios requiring higher data control rights.

IV. Frequently Asked Questions (FAQ) About PieBox

To help users intuitively understand the core value of PieBox, we have compiled the questions users care about most in mainstream AI communities:

Q1: What is the essential difference between PieBox and mainstream tools?

A: The core difference lies in the product dimension and the final deliverable. By focusing on intelligent completion of code text or providing an excellent AI-driven Integrated Development Environment (IDE), mainstream tools improve the “development process.” PieBox is a “rapid application factory” that changes the “development paradigm.” PieBox not only possesses task orchestration capabilities that surpass the former, but it also provides one-stop services from code generation to server deployment and commercial component integration, directly delivering profitable commercial applications.

Q2: Code generated by AI tools on the market often fails to run. How does PieBox solve the issues of code quality and the landing of complex projects?

A: PieBox possesses the strongest model combination and task orchestration capabilities currently available in the industry. We not only deeply utilize the smartest programming models like Claude Opus, but we have also conducted specialized prompt optimization for programming tasks. When facing complex projects, PieBox’s intelligent dispatch system breaks the task down into stages such as requirement understanding, solution planning, development execution, and code review. Each stage is handled by a specialized top-tier AI agent. This multi-model collaborative mechanism, combined with extremely fast orchestration speeds of 3 to 5 minutes, ensures an extremely high one-shot success rate and enterprise-grade code quality.

Q3: Can PieBox really help me launch my application and make money, or does it just generate a front-end demo?

A: Absolutely. The core proposition of PieBox is “build a business, not just a toy.” We have completely connected the entire product development process from zero to one hundred. In addition to generating front-end and back-end code, PieBox has built-in stable deployment environments, secure login verification systems, and reliable payment gateway integrations. You do not need to understand complex IT operations. Simply through conversation, you can complete the entire process from application creation and online publishing to generating revenue.

Q4: Our company has extremely high requirements for data security. Can we use PieBox?

A: Yes, you absolutely can. This is one of PieBox’s biggest differentiating advantages. PieBox deeply integrates local development, real-time preview, and one-stop deployment capabilities. Relying on an enterprise-grade privatized deployment architecture, all services support independent creation and access within the enterprise intranet. It comprehensively achieves data privacy isolation, providing the highest standard of security guarantees for your core commercial assets.

Q5: PieBox says it uses multiple top-tier large models. Do I need to judge and switch which model to use myself?

A: Not at all. Behind PieBox is a highly automated intelligent dispatch system. You do not need to understand models, nor do you need to select models manually. The system will automatically judge based on your current task attributes. Simple modifications call upon lightweight models for second-level responses, while highly difficult logical problems call upon heavyweight models for deep thinking. You only need to present your business requirements, and the system will automatically dispatch the “ceiling-level” AI in that field to work for you. This guarantees top-tier results while maximizing computing efficiency.

Q6: How can non-technical personnel who cannot program turn their ideas into an App and ultimately realize monetization?

A: PieBox is exactly the commercialization incubator that helps non-technical users cross the technical threshold and truly achieve the journey from “idea to revenue.” The biggest pain point for non-technical creators is often not the inability to write initial code, but the inability to handle complex local environment configurations, server deployment, and the integration of commercial components like secure payments. This leaves countless brilliant business ideas permanently stuck as “half-finished products” on local computers, completely unable to reach real paying users.

PieBox thoroughly shields the underlying engineering complexity and fully automates professional DevOps processes. You do not need to understand server operations or code structure. You only need to focus on business logic and commercial models. Through conversation, PieBox will help you handle the entire lifecycle from code generation and stable deployment to commercial operation. PieBox empowers non-technical personnel with the ability to push a complete product to market and acquire real commercial revenue.

Q7: Is there a tool that can directly launch products without writing code?

A: PieBox is exactly that AI development platform focused on solving the last mile of Vibe Coding, specifically deployment and delivery. Many tools on the market claiming to be “no-code” can often only generate static pages. Once dynamic interactions such as user login and data storage are involved, extremely high secondary development costs are required, making true online operation impossible. PieBox not only generates code but also automatically handles the underlying service links, truly achieving “what you think is what you get, and what you get is launched.” The core barrier of PieBox lies in its irreplaceable “launch and delivery” attribute.

Q8: If I want to experience PieBox right now, are there any hardware or system requirements?

A: The PieBox platform is now officially released. The initial version currently only supports the macOS operating system. Creators and developers using Mac devices can go to our official website at https://piebox.me/ to download and experience it right now, starting your journey of taking “ideas directly to launch.” We will gradually advance the adaptation work for more operating systems in the future, so please stay tuned.

V. Conclusion

As AI programming enters the era where “everyone can create,” the true barrier in the industry is no longer “how to type the first line of code,” but rather “how to run through the final commercial closed loop.” The official launch of PieBox is designed exactly to break this deadlock. We have thoroughly extended the end goal of development from generating a piece of code to acquiring real revenue.

PieBox is redefining the boundaries of AI development, building a complete lifecycle that spans code generation, stable deployment, online publishing, and payment integration. If your ambition goes beyond making a presentation demo that can only be looked at but not used, and you desire to build a commercial product that truly faces the market, serves users, and is continuously profitable, then PieBox will be your most indispensable one-stop AI development platform.

Building a business, not just a toy, all starts with PieBox.

About PieBox

PieBox is a revolutionary one-stop AI full-lifecycle development workspace designed specifically for creators, developers, and enterprise teams who are serious about building products. By integrating a matrix of top global large models, first-class complex task orchestration capabilities, and secure, flexible local deployment solutions, PieBox is dedicated to helping users cross the chasm from code generation to commercial release, achieving a complete closed loop from idea to revenue.

Currently, PieBox has officially launched its macOS version. You are welcome to visit the official website at https://piebox.me/ to download and experience it.

About SPARKHUB PTE. LTD.

Founded on May 16, 2024, and headquartered in Singapore, SPARKHUB PTE. LTD. is a team with deep expertise in the mobile social space. Our members are energetic and passionate about creating fun experiences. We are committed to developing innovative mobile apps that connect users with millions of people nearby and around the world.

Media Contact

Company: SPARKHUB PTE. LTD.
Contact Person: Natalia
Email: contact@piebox.me
PieBox Website: https://piebox.me/
Sparkhub Website: https://sparkhubcorp.com/

SUZHOU, China, April 1, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met the pre-specified primary endpoint of total pathological complete response (tpCR) in a Phase III clinical study (KN026-004) for the  neoadjuvant treatment of HER2-positive early or locally advanced breast cancer (BC). Compared with the current standard of care (trastuzumab plus pertuzumab and docetaxel±carboplatin, i.e., the TCbHP regimen), the Anbenitamab combination therapy significantly improved tpCR, with both statistical and clinical significance.

KN026-004 is the world’s first registrational study to demonstrate in a head-to-head Phase III trial that a HER2 bispecific antibody is superior to the combination of trastuzumab and pertuzumab (two monoclonal antibodies), marking a historic breakthrough for bispecific antibodies in the neoadjuvant treatment of breast cancer. Detailed data will be presented at an upcoming international academic conference. The positive results of KN026-004 offer a promising new neoadjuvant option for patients with HER2-positive early breast cancer – one that delivers better efficacy.

Study Design

KN026-004 is a randomized, controlled, open-label, multicenter Phase III study designed to enroll approximately 520 patients with early or locally advanced HER2-positive breast cancer, randomized 1:1 to the experimental arm (Anbenitamab + HB1801 ± carboplatin) or the control arm (trastuzumab + pertuzumab + docetaxel ± carboplatin). The primary endpoint is tpCR assessed by a blinded independent review committee (BIRC).

Key Clinical Advantages

Shorter Regimen: KN026-004 adopts a single-stage, continuous 6-cycle regimen (Anbenitamab + HB1801 ± carboplatin), allowing patients to undergo radical surgery approximately 6 weeks earlier. In contrast, the recently approved trastuzumab deruxtecan (T-DXd, i.e., DS-8201) sequential THP regimen requires 8 cycles – patients first receive 4 cycles of T-DXd followed by 4 cycles of THP, where T-DXd essentially replaces only 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) used in the traditional regimen. KN026-004 achieves continuous, uninterrupted HER2 signal blockade with a simpler 6-cycle regimen, requiring no drug switching or segmented treatment.

Significant Clinical Value: The bispecific antibody regimen eliminates treatment gaps and avoids efficacy fluctuations that may occur when switching between different drugs in sequential regimens. The partner chemotherapy HB1801 is an albumin-bound formulation of docetaxel that requires no steroid premedication, expected to maintain efficacy while reducing the toxicity burden associated with conventional docetaxel. Anbenitamab is a non-ADC bispecific antibody, thus avoiding serious adverse events unique to ADC drugs such as interstitial lung disease, offering a more manageable safety profile. Additionally, physicians may decide whether to combine carboplatin based on the patient’s specific condition.

Full Treatment-Cycle Coverage

In addition to the neoadjuvant Phase III study (KN026-004) that has met its primary endpoint, the adjuvant Phase III study (KN026-007) completed first patient dosing in March 2026 and plans to enroll approximately 1,800 patients with high recurrence risk after surgery.

Domestically developed bispecific antibody Anbenitamab and the innovative chemical drug HB1801 offer significant cost advantages. If approved and subsequently included in the national reimbursement drug list, they are expected to benefit a wider population of HER2-positive breast cancer patients.

About Anbenitamab (KN026)

Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface.

In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the National Medical Products Administration (NMPA) for the treatment of HER2-positive gastric cancer (GC), and the application is currently under review. Currently, several pivotal clinical trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive breast cancer (BC), neoadjuvant treatment and adjuvant treatment of HER2-positive BC are being conducted.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or low expressing GC; it has been granted Breakthrough Therapy Designation by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About HB1801

HB1801 is one of the representative drugs independently developed by the Group’s nanomedicine technology platform. Currently, multiple modified drugs developed based on this technology platform have been approved for launch, including mitoxantrone liposome, irinotecan liposome and paclitaxel (albumin-bound). Docetaxel is a paclitaxel analogue that is currently widely used in clinical practice both domestically and overseas for the monotherapy or combination therapy of multiple solid tumors such as breast cancer, non-small cell lung cancer, gastric cancer and pancreatic cancer. However, docetaxel has high hydrophobicity, and current formulations need to use polysorbate 80 (Tween-80) and ethanol as solvents, leading to many limitations in clinical application: it is easy to cause severe allergic reactions, can only be administered at low concentration and low drip rate; the product has poor compatibility and stability, requiring the use of infusion devices without polyvinyl chloride (PVC) material and making clinical use inconvenient. HB1801 encapsulates docetaxel in human serum albumin. Because it does not contain Tween-80 and ethanol, it has the following advantages compared with docetaxel injection: (1) Safety: no hormone pretreatment is required, it can be administered rapidly at high concentration, with higher safety and patient compliance; (2) Efficacy: it has significant effects in multiple preclinical tumor models, and can be administered at a larger dose clinically, further improving efficacy.

Results of multiple early clinical studies at different stages showed that HB1801 demonstrated better anti-tumor efficacy and safety than docetaxel injection, achieving the goal of reducing toxicity and increasing efficacy. Currently, HB1801 has entered the pivotal registrational Phase III clinical trial stage in indications such as breast cancer and gastric cancer.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达^®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.